Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.
Your search for major depressive disorder returned 225 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder.
Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.
Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
For patients with major depressive disorde, relapse is associated with brain cortical changes over two years.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.